Teva – Recall of losartan
April 29, 2019 - The FDA announced a voluntary, patient-level recall of Teva’s losartan tablets due to the detection of an impurity, N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), found in six lots of active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited that is above the FDA’s interim acceptable exposure limit of 9.82 ppm.
Top